Vyleesi and Bremelanotide: What the Approved Option Means

Sexual health is an integral component of overall physical, emotional, and relational well-being. Yet, for many women, experiencing a persistent or distressing decrease in sexual desire remains a quiet, often unaddressed challenge. Changes in sexual interest can occur across various life stages, influenced by complex interactions between biological factors, daily stress, hormone fluctuations, fatigue, and psychological health. When a lack of interest in intimacy persists over time and causes marked personal distress or interpersonal difficulty, it may reflect a recognized medical condition known as Hypoactive Sexual Desire Disorder (HSDD).

For decades, conversations surrounding sexual health focused heavily on male physiology, leaving limited options for women seeking evidence-based clinical support. Fortunately, contemporary medical research has deepened our understanding of the central nervous system mechanisms that regulate sexual motivation. This scientific progress led to the development of non-hormonal, targeted pharmacological therapies designed specifically for premenopausal women experiencing generalized, acquired low desire. Chief among these options is bremelanotide, marketed under the brand name Vyleesi, which received approval from the United States Food and Drug Administration (FDA) in 2019.

Understanding the distinction between FDA-approved prescription therapies like Vyleesi and non-FDA-approved compounded peptides, such as compounded PT-141, is essential for patients making informed healthcare decisions. Navigating sexual wellness should always occur in a warm, supportive, and scientifically grounded environment. This clinical guide explores how bremelanotide functions in the brain, who may benefit from non-hormonal HSDD treatments, how FDA-approved formulations differ from compounded options, and what to expect during a comprehensive telehealth consultation with a licensed healthcare provider.

Understanding Hypoactive Sexual Desire Disorder (HSDD)

To evaluate potential therapeutic options, it is helpful first to clarify what Hypoactive Sexual Desire Disorder entails and how clinical professionals define it. Sexual desire is a dynamic neurobiological process shaped by a balance of chemical signals within the central nervous system.

What Is HSDD and How Is It Diagnosed?

Hypoactive Sexual Desire Disorder (HSDD) is clinically defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The diagnosis is classified as "acquired" when low desire develops in an individual who previously experienced normal baseline sexual motivation, and "generalized" when it occurs regardless of the type of sexual activity, partner, or situational context.

During a clinical evaluation, medical providers rule out secondary causes, such as major depressive disorder, severe chronic stress, relationship dissatisfaction, surgical menopause, thyroid dysfunction, or medication side effects (such as SSRIs). Distinguishing between situational stress and primary HSDD helps clinical teams recommend appropriate, individualized care strategies.

The Neurobiology of Female Sexual Desire

Historically, low sexual desire was often mischaracterized as purely emotional. While psychological and relationship factors certainly play vital roles, research demonstrates that sexual desire is heavily mediated by central nervous system pathways involving a balance between excitatory and inhibitory neurotransmitters in the brain.

Excitatory pathways are driven by neurotransmitters like dopamine, norepinephrine, and melanocortin peptides, which promote sexual motivation and focus. Inhibitory pathways are influenced by serotonin and opioids, which dampen sexual responsiveness. In women experiencing HSDD, excitatory signaling may be reduced, or inhibitory signaling may be heightened. Non-hormonal medical options like bremelanotide specifically target these central pathways to help realign the neurochemical balance that supports natural sexual motivation.

What Is Vyleesi (Bremelanotide Injection)?

Bremelanotide represents a significant milestone in modern women's health as a non-hormonal, centrally acting agent. Marketed under the brand name Vyleesi, this prescription medication provides a targeted therapeutic approach for premenopausal women diagnosed with generalized, acquired HSDD.

Mechanism of Action: Melanocortin Receptor Agonism

Unlike traditional hormone replacement therapies that adjust systemic estrogen or progesterone levels, bremelanotide functions as a melanocortin receptor agonist. Specifically, bremelanotide binds to and activates melanocortin 4 receptors (MC4R) and melanocortin 3 receptors (MC3R) located on neurons in the hypothalamus involved in sexual response.

By activating these central melanocortin receptors, bremelanotide enhances downstream dopamine release while modulating inhibitory pathways. This activity increases central sexual motivation without directly acting on vascular smooth muscle or peripheral reproductive organs. Clinical evidence indicates that by working directly within the brain's motivational circuits, bremelanotide helps facilitate neural responsiveness so natural desire can emerge when appropriate stimuli are present.

FDA Approval and Indication

In June 2019, the FDA approved Vyleesi (bremelanotide injection) specifically for premenopausal women with acquired, generalized HSDD based on clinical trials evaluating safety and efficacy in thousands of participants. Vyleesi is not indicated for postmenopausal women, nor is it approved to treat low sexual desire caused by psychiatric illness, relationship distress, or medication side effects.

Administration and Practical Dosing Guidelines

Vyleesi is designed for on-demand, as-needed (prn) use rather than continuous daily administration. It is supplied in a single-dose autoinjector prefilled with 1.75 mg of bremelanotide in 0.3 mL of solution.

Patients administer the injection subcutaneously into the fat layer of the thigh or abdomen at least 45 minutes prior to anticipated sexual activity. Key clinical parameters include:

• Dosing Timing: Administer at least 45 minutes before anticipated intimacy. Optimal response timing varies among individuals.
• Maximum Frequency: Do not administer more than one dose within a 24-hour period.
• Monthly Limit: Guidelines advise against using more than 8 doses per month, as frequent administration does not enhance efficacy and may increase side effect risks.
• Discontinuation Criteria: If a patient experiences no improvement in sexual desire or distress after 8 weeks, treatment should be re-evaluated and discontinued.

Vyleesi vs. Compounded PT-141: What You Need to Know

As interest in non-hormonal options for sexual health has grown, many patients encounter discussions regarding "PT-141" alongside Vyleesi. Understanding the relationship and distinction between these terms is essential when evaluating treatment options.

The Relationship Between Bremelanotide and PT-141

PT-141 was the original research code designation given to bremelanotide during early clinical development. Scientifically, bremelanotide and PT-141 refer to the exact same peptide molecule (a synthetic peptide analog of alpha-melanocyte-stimulating hormone). However, while the active chemical structure is identical, the regulatory status, manufacturing oversight, and quality control of commercially available formulations differ significantly.

FDA Approval Status and Regulatory Distinctions

The regulatory distinction between brand-name Vyleesi and compounded PT-141 is critical for patient safety and clinical transparency:

• Vyleesi (Brand Bremelanotide): Vyleesi is an FDA-approved prescription drug product. Its formulation, manufacturing facilities, prefilled autoinjector, stability profile, and clinical dosing guidelines have undergone formal FDA review. FDA approval guarantees standardized strength, purity, sterility, and consistency.
• Compounded PT-141: Compounded formulations of PT-141—whether prepared as custom injections, nasal sprays, or sublingual strips—are prepared by compounding pharmacies pursuant to individual patient prescriptions. Compounded medications, including compounded PT-141, are NOT FDA-approved drug products. The FDA does not evaluate compounded formulations for safety, clinical efficacy, or manufacturing uniformity prior to distribution.

Why Quality Assurance Matters

While compounding pharmacies serve an important role in healthcare when custom dosages are required, patients should recognize that unapproved compounded peptides may carry variable stability, concentration, or sterility standards compared to FDA-approved commercial drugs. Licensed clinicians evaluate these factors when discussing treatment choices to ensure safe and transparent care.

What to Expect: Efficacy, Dosing, and Side Effects

When considering any medical treatment for low desire, establishing realistic clinical expectations is essential. Bremelanotide is designed to support natural neurochemical responsiveness, but individual responses vary based on underlying health, psychological well-being, and lifestyle factors.

Clinical Trial Findings and Efficacy Data

The approval of Vyleesi was based on two pivotal Phase 3 clinical trials (RECONNECT studies) involving over 1,200 premenopausal women with HSDD. In these trials, participants using bremelanotide reported statistically significant increases in sexual desire scores and reductions in distress related to low sexual desire compared to placebo.

Bremelanotide does not act as an instant aphrodisiac or guarantee automatic arousal. Rather, research indicates that it helps prime the brain's motivational pathways, enabling a woman to experience natural desire in response to intimacy and erotic stimuli.

Common Side Effects and Management Strategies

Like all active prescription medications, bremelanotide carries potential side effects. In clinical trials, the most commonly reported adverse reactions included:

• Nausea: Approximately 40% of trial participants reported nausea, most commonly occurring after initial doses. Nausea was generally mild to moderate and tended to lessen with subsequent uses. Administering the injection with a light snack may help ease mild nausea.
• Flushing: Facial or skin flushing was reported by about 20% of patients, typically resolving within a few hours.
• Injection Site Reactions: Mild erythema or swelling at the subcutaneous site affected roughly 13% of users. Rotating injection locations between thigh and abdomen helps minimize localized skin reactions.
• Headache: Mild to moderate headaches occurred in approximately 11% of trial participants.
• Focal Hyperpigmentation: About 1% of patients developed localized darkening of the skin, face, or gums. Hyperpigmentation is more common among individuals with darker skin tones and those using frequent doses, and may not fully resolve after stopping treatment.

Contraindications and Safety Considerations

Bremelanotide causes transient increases in blood pressure and temporary decreases in heart rate following administration. Consequently, bremelanotide is contraindicated in women with uncontrolled hypertension or known cardiovascular disease.

Additionally, bremelanotide can slow gastric emptying, which may alter the absorption of concurrent oral medications. In particular, it is not recommended for individuals taking oral naltrexone, as bremelanotide may significantly decrease naltrexone drug concentrations and reduce its effectiveness. A thorough clinical review by a licensed practitioner ensures that cardiovascular health and concurrent medications are safely screened prior to initiating therapy.

Taking a Holistic Approach to Women's Sexual Health

Medical treatments such as bremelanotide represent valuable clinical tools, but pharmacological options are most effective when integrated into a comprehensive, holistic approach to women's health. Sexual desire is multifaceted, influenced by psychological comfort, emotional intimacy, physical energy, hormone balance, and personal stress levels.

Addressing the Whole Person

A thorough evaluation of sexual wellness considers multiple contributing dimensions:

• Physical Health & Hormones: Ensuring optimal thyroid function, iron levels, sleep quality, and physical comfort during intimacy.
• Psychological Well-Being: Addressing underlying anxiety, depression, body image concerns, or chronic daily stress that can suppress sexual responsiveness.
• Relational Context: Encouraging open communication, emotional connection, and mutual understanding between partners.
• Lifestyle & Energy: Prioritizing restful sleep, balanced nutrition, and regular physical movement to support overall vitality and autonomic health.

Navigating a Telehealth Consultation with EOS Health

Seeking help for sexual health concerns can feel intimidating, but receiving medical evaluation should be empowering, confidential, and convenient. Modern telehealth platforms provide a private space for women to discuss low desire with compassionate, licensed healthcare providers.

During an online clinical consultation with EOS Health, a licensed clinician reviews your medical history, current symptoms, blood pressure readings, and treatment goals. If a prescription therapy such as Vyleesi is deemed clinically appropriate, your provider guides you through proper administration, dosing guidelines, side effect management, and ongoing follow-up care.

If you have been experiencing persistent low desire that causes distress, you do not have to navigate it alone. Take the first proactive step toward understanding your options by visiting the EOS Health Women's Sexual Health evaluation portal to consult with a licensed provider today.

Hypoactive Sexual Desire Disorder (HSDD)

A recognized clinical condition characterized by a persistent or recurrent lack of sexual desire or fantasies that causes marked distress or interpersonal difficulty, not attributable to another medical condition, psychiatric illness, or relationship conflict.

Bremelanotide

A synthetic peptide melanocortin receptor agonist that acts on central nervous system pathways to restore natural sexual motivation and desire in premenopausal women with HSDD.

Melanocortin Receptor Agonist

A class of pharmacological compounds that bind to and activate melanocortin receptors (such as MC3R and MC4R) in the brain, influencing physiological processes including central sexual arousal and appetite regulation.

Acquired Generalized HSDD

A subtype of Hypoactive Sexual Desire Disorder where low desire develops after a period of normal sexual functioning (acquired) and occurs regardless of the type of sexual activity, partner, or situation (generalized).

Subcutaneous Injection

A method of medication delivery where a small dose of medicine is injected into the fatty tissue layer just beneath the skin, such as in the abdomen or thigh, using a fine needle or prefilled autoinjector.